Baird lowered the firm’s price target on Bio-Techne (TECH) to $49 from $70 and keeps a Neutral rating on the shares. The firm updated its model following Q3 organic growth miss and Q4 guidance was below expectations.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TECH: